NanoViricides shares are trading higher after the company announced that it ultra-broad-spectrum antiviral NV-387 was found to be effective in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse model.
Portfolio Pulse from Benzinga Newsdesk
NanoViricides shares are trading higher after the company announced that its ultra-broad-spectrum antiviral NV-387 was found to be effective in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse model.
June 20, 2024 | 5:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NanoViricides shares are trading higher after the company announced that its ultra-broad-spectrum antiviral NV-387 was found to be effective in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse model.
The positive results from the study of NV-387 in a mouse model of Influenza A H3N2 are likely to boost investor confidence in NanoViricides' product pipeline, leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100